|
|
News Breaks | | | | March 5, 2013 | | 09:27 EDT |  | SNTS | Santarus gaps up after earnings beat, levels to watch
The company last night reported and earnings beat of 7 cents, versus expectations of a 1 cent gain for its Q4. At the current price of $15.12, there is no resistance on the chart. Support is at $14.70. | |
|
News For SNTS From The Last 14 Days Check below for free stories on SNTS the last two weeks. |
|
|
| June 18, 2013 | | 05:30 EDT |  | SNTS | Santarus, Pharming Group announce FDA acceptance for review of Ruconest BLA
 Subscribe for More Information | | | June 13, 2013 | | 08:24 EDT |  | SNTS | Santarus price increases positive, says Roth Capital
Subscribe for More Information | | | June 10, 2013 | | 07:14 EDT | | SNTS | Santarus checks positive, says Stifel
After surveying 30 gastroenterologists last month, Stifel reports that the doctors were very satisfied with Santarus' Uceris, an ulcerated colitis treatment. Moreover, more than 50% of the doctors said they were comfortable proscribing the drug for off-label conditions, the firm stated. Stifel keeps a Buy rating on the shares. | |
|
|
|
|
|
|
